Literature DB >> 16378633

Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.

Fatim Cham1, Peng Fei Zhang, Leo Heyndrickx, Peter Bouma, Ping Zhong, Herman Katinger, James Robinson, Guido van der Groen, Gerald V Quinnan.   

Abstract

In this study, we tested the hypothesis that donors with broadly cross-reactive HIV-1 neutralizing (BCN) sera are infected with viruses encoding envelope glycoproteins (Envs) with unusual immunogenic properties. Cloned env genes were from samples of donors previously identified as having BCN antibodies (BCN donors) and from other donors not known to have such antibodies (non-BCN donors). Neutralization properties of viruses pseudotyped with BCN and non-BCN Envs were determined using BCN, non-BCN sera and broadly cross-neutralizing monoclonal antibodies (Mabs). BCN sera neutralized with higher frequency and geometric mean titers than non-BCN sera. Viruses pseudotyped with BCN Envs were mostly resistant to neutralization by anti-gp120 Mabs but tended to be more sensitive to the anti-gp41 Mabs, 2F5 and 4E10 than non-BCN Env-pseudotyped viruses. Sequence analysis of clones obtained from sequential samples of two BCN donors revealed respective 2F5 epitope mutations T662A and K665T. The K665T mutation evolved as the predominant genotype in the respective donor, consistent with an escape mutation event. The A662T mutation reduced sensitivity to 4E10, as well as 2F5 and homologous sera, consistent with neutralization escape mutation and targeting of the 2F5 epitope region by the serum. Our study suggests that viruses infecting these BCN donors encoded Envs that may have been unusually competent for induction of antibodies against the membrane proximal epitope region (MPER) of gp41, and these Envs may be useful vaccine components.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16378633     DOI: 10.1016/j.virol.2005.11.019

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Detection of HIV gp120 in plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory cytokines.

Authors:  Jenna Rychert; Daryld Strick; Sue Bazner; James Robinson; Eric Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08-19       Impact factor: 2.205

2.  Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

Authors:  Jennifer L Kirchherr; Jennifer Hamilton; Xiaozhi Lu; S Gnanakaran; Mark Muldoon; Marcus Daniels; Webster Kasongo; Victor Chalwe; Chanda Mulenga; Lawrence Mwananyanda; Rosemary M Musonda; Xing Yuan; David C Montefiori; Bette T Korber; Barton F Haynes; Feng Gao
Journal:  Virology       Date:  2010-10-30       Impact factor: 3.616

3.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

4.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

5.  Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Authors:  Amandeep K Dhillon; Helen Donners; Ralph Pantophlet; Welkin E Johnson; Julie M Decker; George M Shaw; Fang-Hua Lee; Douglas D Richman; Robert W Doms; Guido Vanham; Dennis R Burton
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

6.  Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.

Authors:  Vidita Choudhry; Mei-Yun Zhang; Ilia Harris; Igor A Sidorov; Bang Vu; Antony S Dimitrov; Timothy Fouts; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2006-08-04       Impact factor: 3.575

7.  Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.

Authors:  Vidita Choudhry; Mei-Yun Zhang; Igor A Sidorov; John M Louis; Ilia Harris; Antony S Dimitrov; Peter Bouma; Fatim Cham; Anil Choudhary; Susanna M Rybak; Timothy Fouts; David C Montefiori; Christopher C Broder; Gerald V Quinnan; Dimiter S Dimitrov
Journal:  Virology       Date:  2007-02-15       Impact factor: 3.616

8.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

9.  Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.

Authors:  Anthony DeVico; Timothy Fouts; George K Lewis; Robert C Gallo; Karla Godfrey; Manhattan Charurat; Ilia Harris; Lindsey Galmin; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

10.  Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus.

Authors:  R L Tallmadge; M A Brindley; J Salmans; R H Mealey; W Maury; S Carpenter
Journal:  Clin Vaccine Immunol       Date:  2008-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.